Sunday 22 July 2018 - 10:05
In Business 38 Years - Since 1980
Doxorubicin and Venetoclax Are Now Back in Stock -- July 5, 2018
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
M-2433 Mocetinostat, Free Base, >99%
Related Terms : [MG-0103] [MGCD0103]
- Size
- US $
- €
- £
- ¥
- 10 mg
- 42
- 35
- 31
- 4,600
- In stock
- 25 mg
- 58
- 49
- 42
- 6,400
- In stock
- 50 mg
- 99
- 83
- 73
- 10,900
- In stock
- 100 mg
- 159
- 134
- 117
- 17,500
- In stock
- 200 mg
- 287
- 243
- 212
- 31,700
- In stock
- 500 mg
- 497
- 421
- 367
- 54,800
- In stock
- 1 g
- 869
- 736
- 642
- 95,800
- In stock
- 2 g
- 1,630
- 1,382
- 1,204
- 179,800
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 396.44
- C23H20N6O
- [726169-73-9]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
- Mocetinostat selectively inhibits histone deacetylases (HDACs) 1-3 and 11 at submicromolar concentrations. It blocks cancer cell proliferation in vitro and has significant antitumor activity in vivo. Zhou, N., et al. "Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor." J. Med. Chem. 51: 4072-4075 (2008).
- Mocetinostat induces hyperacetylation of histones, causes expression of the tumor suppressor protein p21(WAF1/CIP1), and inhibits proliferation of human cancer cells growing in culture. Raeppel, S., et al. "SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)." Bioorg. Med. Chem. Lett. 19: 644-649 (2009).
- Mocetinostat demonstrated antitumor activity against hematological and lymphoproliferative cancers. Le Tourneau, C. and Siu, L.L. "Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor." Expert Opin. Investig. Drugs 17: 1247-1254 (2008).
- Mocetinostat dose-dependently inhibited HDAC activity in several human cancer cell lines and in human peripheral white blood cells. The inhibitory effect of mocetinostat lasted for at least 8 hours in mice and 48 hours in patients with solid tumors. Bonfils, C., et al. "Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay." Clin. Cancer Res. 14: 3441-3449 (2008).
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
